Basilea news from FierceBiotech
News
Basilea shares plunge on antibiotic delay
Switzerland's Basilea took its turn on the public markets' whipping post, shedding 27 percent of share value after announcing that its antibiotic ceftobiprole had failed to quickly win over FDA Read more...
FDA cancels meeting as hopes rise for Basilea
The FDA has canceled a scheduled advisory board meeting on Basilea's ceftobiprole antibiotic, a move that Read more...
Basilea reports positive Phase III antibiotic data
A late-stage trial of the experimental antibiotic ceftobiprole, which is being jointly developed by Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets